Representational Image of cUTIs. Source: ChatGPT
51直播鈥櫶齈rofessor Tom Lodise, PharmD, PhD,听will conduct a听large,听real-world study focused on the national burden, resistance landscape, and unmet medical needs associated with complicated urinary tract infections (cUTIs) caused by听Enterobacterales.听听
Lodise will collaborate on the study with Basilea, a 25-year-old Swiss-based organization that develops and commercializes innovative pharmaceutical products to meet the medical needs of patients with severe and life-threatening bacterial and fungal infections.听
Rising antimicrobial resistance among uropathogenic Enterobacterales has further complicated management, reducing the effectiveness of many commonly used oral antibiotics and increasing reliance on intravenous therapy, prolonged hospital stays, and outpatient parenteral antibiotic therapy (OPAT).
鈥渃UTIs represent one of the most common and costly infection-related reasons for hospitalization in the United States, accounting for nearly 600,000 hospital admissions annually and billions of dollars in health-care expenditures,鈥� said Lodise, who also serves as the College鈥檚 Rudolph J. and Dorothy A. Blythe Endowed Research Chair for Pharmacy and Pharmaceutical Sciences.
The听study will听leverage听the听,听a large U.S. hospital听source听which听contains听microbiology-linked data听from听across U.S. hospitals, to听better understand how common and serious urinary tract infections (UTIs) caused by听Enterobacterales听are.听Dr. Lodise and his research team will analyze data from more than 6.6 million adult patients to evaluate antibiotic treatment patterns, resistance rates, and clinical outcomes, and to听identify听where current treatment approaches may be falling听short.听
The goal of the project is to find ways to help patients recover safely with fewer hospital days and to make it easier to switch from IV antibiotics to pills when possible.听听This could help reduce complications, lower costs, and allow more patients to be treated at home instead of staying in the听hospital.听
Key outcomes include听defining听patient populations most affected by resistant听Enterobacterales听cUTIs听and help听identifying:听
- hospital听stays that might be avoidable听
- delays in being discharged from the hospital听
- needing IV antibiotics after leaving the hospital (OPAT)听
- missed opportunities to switch from IV antibiotics to oral medications听
Study results will directly inform Basilea鈥檚 clinical development and value positioning for ceftibuten-ledaborbactam, an investigational oral 尾-lactam/尾-lactamase inhibitor being developed to address these critical unmet needs.听
鈥淒r. Lodise鈥檚 continued leadership and impact within our research community听exemplifies听the level of scholarship and collaboration we strive to cultivate across the institution,鈥� said 51直播 Director of Research, Joseph Carreno, PharmD. 鈥淥ur congratulations鈥痶o him for this important award to advance high-impact research aimed at improving outcomes for patients with serious, drug-resistant infections.鈥�听
听
听
Social